← Leaderboards
Robert Ernest William Hancock
University Of British Columbia
$2,019,991
Attributed
$2,019,991
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $265.5K · FY2012–21$500K$375K$250K$125K$0
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
Funding mix
By agency
NIH$2,019,991 · 3
By mechanism
U19$935,043 · 1
R33$788,428 · 1
R21$296,520 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of British Columbia
Same institution · by research overlap
- Philip Ross Hardwidge$7,824,116
Others in their field
Top investigators on “Complex”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$385,971,304
- Chanza Baytop · Westat, Inc.$271,217,917
- David R. Weir · University Of Michigan At Ann Arbor$186,776,551
- Barton F Haynes · Duke University$162,931,717
Research focus
ComplexGenetic TranscriptionAdultBaseAntibiotic ResistanceAdjuvant TherapyAcinetobacterAntimicrobial PeptideAnimal ModelAntiviral ResistanceAutomobile DrivingBacteriaAntibioticsAntimicrobialBioinformaticsBindingBiological MarkersBiologyBloodBlood CellsBlood SpecimenBritish ColumbiaBurkholderiaAntibiotic Therapy
Grant awards (10)
Transcriptomics to define biomarkers of neonatal vaccine immunogenicity$252,726
U19 · FY2021 · AI · contact PI
Transcriptomics to define biomarkers of neonatal vaccine immunogenicity$124,723
U19 · FY2020 · AI · contact PI
Transcriptomics to define biomarkers of neonatal vaccine immunogenicity$139,947
U19 · FY2019 · AI · contact PI
Transcriptomics to define biomarkers of neonatal vaccine immunogenicity$191,703
U19 · FY2018 · AI · contact PI
Transcriptomics to define biomarkers of neonatal vaccine immunogenicity$225,944
U19 · FY2017 · AI · contact PI
Novel adjunctive therapy for drug resistant Gram-negative pathogens$265,485
R33 · FY2016 · AI · contact PI
Novel adjunctive therapy for drug resistant Gram-negative pathogens$263,098
R33 · FY2015 · AI · contact PI
Novel adjunctive therapy for drug resistant Gram-negative pathogens$259,845
R33 · FY2014 · AI · contact PI
Novel adjunctive therapy for drug resistant Gram-negative pathogens$126,281
R21 · FY2013 · AI · contact PI
Novel adjunctive therapy for drug resistant Gram-negative pathogens$170,239
R21 · FY2012 · AI · contact PI